QuiaPEG

Newsroom

Se nyheter från:
Page:
1234567
Oct 23, 2019

QuiaPEG Pharmaceuticals Holding AB (publ) develops improved and patentable versions of clinically validated or already approved drugs, so-called. biobetters. This is done on the basis of the company's own patent-protected technology platform, Uni-Qleaver®, which makes it possible to control a drug's release through a degradable chemical linker.

Sept 18, 2019

QuiaPEG Pharmaceuticals Holding AB (publ) has received a so-called "Notice of Allowance" on the granting of patents in Canada.QuiaPEG Pharmaceuticals Holding AB (publ), which develops improved and patentable versions of clinically validated or already approved drugs using the company's unique technology platform, announces that the company has received a so-called “Notice of Allowance” from the Canadian Patent Office.

July 16, 2019

QuiaPEG Pharmaceuticals Holding AB (publ) has been granted another patent in the EU.

Apr 05, 2019

QuiaPEG Pharmaceuticals Holding AB (publ) receives so-called "Notice of Allowance" on granting of a patent in the United States

Page:
1234567
Contact
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 54 Uppsala
Sweden
+46 (0) 70 693 12 53
info@quiapeg.com

User terms & privacy policy
Send a message